METROPOLIS

March 3 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• METROPOLIS HEALTHCARE LTD - UNIT ENTERS BUSINESS TRANSFER AGREEMENT

• METROPOLIS HEALTHCARE LTD - ACQUIRES LABORATORIES AND COLLECTION CENTERS IN AGRA

Source text: ID:nBSE1Fp0Q3

Further company coverage: METP.NS

(([email protected];;))

** Shares of Metropolis Healthcare Ltd METP.NS rise 4.4% to 1,813.75 rupees

** Medical diagnostics firm reported a 15.5% rise in Q3 profit on higher sales of costlier tests after market hours on Tuesday; rev up 10%

** METP and larger rival Dr Lal PathLabs DLPA.NS rated "Hold", while analysts rate smaller rival Vijaya Diagnostic VIJA.NS "Buy" - LSEG

** Stock trims YTD losses to 12.8%, but trails DLPA's ~7% loss and VIJA's 11% climb this year

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Feb 4 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• DEC-QUARTER CONSOL NET PROFIT 313.6 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 3.23 BILLION RUPEES

• APPOINTS SAMEER PATEL AS CFO EFFECTIVE FEB 10, 2025

• ADITYA SHINDE TO STEP DOWN AS INTERIM CFO EFFECTIVE FEB 09, 2025

Source text: ID:nNSE9ZztPM

Further company coverage: METP.NS

(([email protected];))

** Metropolis Healthcare METP.NS rises 2.7% to 2,249.70 rupees

** Co will acquire 100% stake in oncology testing lab Core Diagnostics for equity value of 2.47 bln rupees ($29 mln)

** Says 45% to be funded by equity swap and 55% by cash consideration

** Stock eyes a three-day rally

** METP up ~32% YTD

($1 = 84.7970 Indian rupees)

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Dec 9 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• METROPOLIS HEALTHCARE LTD - TO ACQUIRE 100% STAKE IN CORE DIAGNOSTICS FOR 2.47 BILLION RUPEES

Source text: ID:nBSEbJbHnT

Further company coverage: METP.NS

(([email protected];))

Nov 8 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• SEPT-QUARTER CONSOL NET PROFIT 465.2 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 3.5 BILLION RUPEES

• NAMES ADITYA SHINDE AS INTERIM CHIEF FINANCIAL OFFICER

Source text: ID:nBSE5tDrF6

Further company coverage: METP.NS

(([email protected];;))

** Shares of Krsna Diagnostics KRSN.NS up ~ 5% at 672.70 rupees

** Co on Tuesday reported 24% Y/Y surge in Q1 profit after tax, while rev rose 22%

** Stk down 6.3% YTD, biggest drag among diagnostic stocks

** Peers Vijaya Diagnostic VIJA.NS up 18% YTD, Thyrocare THYO.NS up ~ 21%, Metropolis Health METP.NS up 23%, Dr Lal Path DLPA.NS up 23%

** KRSN, Thyrocare "strong buy" rated on average; METP, DLPA "hold" rated, while VIJA "buy" rated - LSEG

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

July 9 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• REVENUES GREW BY ABOUT 13% FOR Q1FY25 Y/Y

• CO IS DEBT FREE, HAS CASH RESERVES OF ABOUT 1.4 BILLION RUPEES AS ON JUNE 30, 2024

Further company coverage: METP.NS

(([email protected];))

BENGALURU, May 10 (Reuters) - Dr. Lal PathLabs DLPA.NS, India's biggest diagnostics firm by revenue, posted a bigger profit for the fourth straight quarter on Thursday, led by the addition of more labs and increased demand for medical tests.

The company's consolidated net profit jumped 49% year-on-year to 845 million rupees ($10.1 million) in the fourth quarter.

Its shares climbed as much as 7.8% after the results before trimming some gains to trade up about 6%. Rival Metropolis Healthcare METP.NS was up about 2% and Thyrocare Technologies THYO.NS gained about 1%.

Analysts expect Indian diagnostic firms to benefit from geographic expansions and price hikes.

"We're expanding our reach in core markets by strengthening our presence in Tier 3 and Tier 4 towns," Dr. Lal PathLabs Chief Executive Officer-designate Shankha Banerjee said.

The number of samples tested grew 8.5% during the quarter, and was up roughly 10% for the fiscal year.

The company, which operates more than 280 labs in India, said total revenue climbed by 11% to 5.45 billion rupees.

Thyrocare is scheduled to report its fourth-quarter results next week.

($1 = 83.4872 Indian rupees)

(Reporting by Kashish Tandon and Nandan Mandayam in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

** Shares of Metropolis Healthcare METP.NS rise as much as 7.4% to 1,933.50 rupees, highest since May 18, 2022

** Diagnostic services co says revenue grew ~15% Y/Y in Q4FY24

** Adds, EBITDA margins show consistent upward trend both Q/Q and Y/Y, driven by higher volumes, price increase

** Stock on track to gain for fifth straight session

** More than 1.6 mln shares traded as of 10:51 a.m. IST, 5.6x their 30-day moving avg; busiest day yet since Feb. 6

** Mean rating of 13 analysts is "hold"; median PT 1,670 rupees, while bigger peer Dr. Lal Pathlabs DLPA.NS is "sell" - LSEG data

** METP last up 4.3%, adding to YTD gains of ~11.9%; DLPA down 8%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

April 10 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• METROPOLIS HEALTHCARE LTD - EXPERIENCED AROUND A 10% Y/Y INCREASE IN OVERALL REVENUE IN Q4FY24

• METROPOLIS HEALTHCARE LTD - CORE BUSINESS REVENUE GREW ABOUT 15% Y/Y FOR Q4FY24

Source text for Eikon: [ID:]

Further company coverage: METP.NS

(([email protected];))

** Dr. Lal PathLabs' shares DLPA.NS jump 5% to 2,236 rupees

** Stock set for its steepest pct rise since early Nov

** Kotak Institutional Equities double upgrades to "add" from "sell", lifts fair value to 2,360 rupees from 1,975 rupees

** Brokerage expects improvement in pricing trends for diagnostics and views new CEO appointment as a positive

** Stock tumbled ~13% in 9 sessions since CEO left on March. 4; but has clawed back losses to ~9% since a new CEO was named on March 17

** Still, Kotak's new FV is 3.8% discount to analysts' median PT, per LSEG data

** Analysts avg rating on DLPA is "sell", while it is "hold" for peers Dr. Reddy's Labs REDY.NS and Metropolis Healthcare METP.NS

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

March 4 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• GETS TAX ORDER FOR ACTUAL DEMAND FOR AY 2023-24 AT 241.9 MILLION RUPEES

Source text for Eikon: ID:nBSE8bVyFY

Further company coverage: METP.NS

(([email protected];))

Feb 29 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• GETS ORDER FROM INCOME TAX AUTHORITY

• INCOME TAX DEMAND OF 99.9 MILLION RUPEES RAISED BY ACIT

Source text for Eikon: ID:nBSE6rSWSZ

Further company coverage: METP.NS

(([email protected];))

BENGALURU, Feb 1 (Reuters) - Dr. Lal PathLabs DLPA.NS, India's biggest diagnostics firm by revenue, posted a higher profit for the third straight quarter on Thursday, due to more diagnostics and tests in the monsoon and winter seasons as well as an increase in COVID cases.

The company's consolidated net profit jumped 54% year-over-year to 813 million rupees (nearly $10 million) in the third quarter.

Its total revenue climbed by 10% to 5.39 billion rupees

The October-December quarter encompasses the tail end of the monsoon as well as winter, which brings with them ailments such as influenza and stomach flu.

Moreover, a resurgence in COVID-19 cases towards the end of December also boosted the demand for tests.

That benefited Dr. Lal PathLabs and its rivals, including Metropolis Healthcare METP.NS and Thyrocare Technologies THYO.NS.

Thyrocare's results are due later in the day, and Metropolis will report its results on Friday.

The stock prices of all three companies were little changed on the day.

Dr. Lal PathLabs's shares climbed 14% in 2023, sandwiched between Metropolis' 26% rise and Thyrocare's 4% bump.

($1 = 82.9746 Indian rupees)

(Reporting by Varun Vyas in Bengaluru; Editing by Savio D'Souza)

(([email protected];))

** Shares of medical diagnostics firm Metropolis Healthcare Ltd METP.NS up 3.2% at 1,552 rupees

** METP provides clarification regarding media reports of fake data entry and lab tests in Delhi govt-run clinics

** Co says contract to collect and analyse samples from these clinics formed only 0.5% of its overall consol revenue; looking to recover dues worth 22.6 million rupees and exit contract

** Stock up after falling for eight consecutive sessions in which it lost 12.6%

** Around 657,000 shares change hands, 1.2x the 30-day avg

** Twelve analysts covering METP rate it "hold" on avg; median PT is 1,485 rupees - LSEG data

** Stock fell over 6% in 2023, the most among other listed medical diagnostic firms

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Jan 8 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• MARGINS FOR Q3FY24 ARE SLIGHTLY LOWER ON A Y-O-Y BASIS

• WITNESSED EARLY DOUBLE-DIGIT GROWTH IN REVENUES FOR ITS CORE BUSINESS IN Q3

• COMPETITIVE INTENSITY IN B2C SEGMENT HAS BEEN REDUCING, COUPLED WITH A STEADY INCREASE IN PRICES

• COMPANY IS POISED TO TAKE A PRICE RISE IN B2C SEGMENT IN Q4 ON A PAN INDIA BASIS

Further company coverage: METP.NS

(([email protected];))

** Shares of Indian diagnostic firms including Dr. Lal PathLabs DLPA.NS, Metropolis Healthcare METP.NS and Thyrocare Technologies THYO.NS rise over 4%

** METP hits its peak since April 5, 2022, and THYO achieves its highest level since Dec. 22, 2022

** DLPA posts biggest intraday gain since Nov. 3

** Between 2020 and 2021, diagnostic firms in India made profits from testing for Coronavirus infection among millions of patients; since India eased pandemic curbs, profits have waned

** India reports 594 new daily cases of COVID, up about 151% from a week ago - Health Ministry data

** "During the COVID-19 pandemic, diagnostic companies emerged as major beneficiaries, benefiting from the surge in demand for COVID testing. Alongside this, there was an increase in the demand for various medical supplies, including devices, injections, oximeters, and more," says Abdulkader Puranwala, assistant vice president, ICICI Securities

(Reporting by Navamya Ganesh Acharya and Rama Venkat in Bengaluru)

(([email protected]; +91 8805175330 ;))

** Shares of Metropolis Healthcare METP.NS down 2.4% at 1,535.25 rupees

** Diagnostics firm reported a 12.1% fall in Q2 net profit; total expenses rose nearly 5%, dragged by a jump in employee costs

** Of the 13 analysts tracking METP, five have "buy" or "strong buy" rating, one "hold," seven "sell" or "strong sell;" median TP is 1,462.50 rupees - LSEG data

** Stock up about 16% YTD

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

Oct 6 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• SEPT QUARTER CORE BUSINESS REVENUE GREW BY 13% Y/Y

Source text for Eikon: ID:nNSEzB0sk

Further company coverage: METP.NS

(([email protected];))

Aug 2 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• JUNE-QUARTER CONSOL NET PROFIT 288 MILLION RUPEES VERSUS PROFIT 334 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 2.77 BILLION RUPEES VERSUS 2.80 BILLION RUPEES

Source text for Eikon: ID:nNSE60nS8j

Further company coverage: METP.NS

(([email protected];))

** Shares of Metropolis Healthcare METP.NS rise as much as 3.49% to 1,486.60 rupees

** Diagnostics firm's business update on Friday shows core business revenue grew 12% Y/Y in June quarter

** Core business volume rose 13% Y/Y, while revenue per test advanced 3%

** Of the 13 analysts tracking METP, two have "strong buy" rating, three "buy," two "hold," five "sell" and one "strong sell;" median TP is 1,330 rupees - Refinitiv data

** METP up 12% YTD vs 14% rise in healthcare index .NIFHEIN

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected] ; +91 9769003463))

May 16 (Reuters) - Metropolis Healthcare Ltd METP.NS:

• INDIA'S METROPOLIS HEALTHCARE LTD MARCH-QUARTER CONSOL NET PROFIT 333.6 MILLION RUPEES VERSUS PROFIT 358 MILLION RUPEES

• METROPOLIS HEALTHCARE LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 2.83 BILLION RUPEES VERSUS 2.85 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: METP.NS

(([email protected];))

BENGALURU, May 11 (Reuters) - India's Dr. Lal PathLabs Ltd DLPA.NS on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from COVID-related testing outpaced growth in its core business.

The medical diagnostics firm, India's largest by revenue, posted a consolidated net profit of 567 million rupees ($6.93 million) in the three months to March 31, down from 613 million rupees a year earlier.

Earnings margin before interest, taxes, depreciation, and amortisation contracted to 23.6% from 24.9% a year ago.

Dr. Lal PathLabs is the first among its peers to report results and will set the tone for an intensely competitive industry that made a windfall during the pandemic but has since sharply slipped.

Shares of the company and its listed rivals Metropolis Healthcare METP.NS, Thyrocare Technologies THYO.NS and Vijaya Diagnostic Centre VIJA.NS have fallen between 45% and 68% from their all-time highs in 2021, as of their last close.

Analysts have since set their sights on companies' ability to widen their range of tests and geographic reach, noting that Dr. Lal PathLabs is best placed among its competitors to grow in the long term.

Over the period of more than a year, the company, which has a strong presence in northern and eastern India besides its New Delhi base, has sought to expand to smaller cities and other regions in the country through acquisitions.

Revenue grew a mere 1.1% to 4.91 billion rupees, with the non-COVID segment contributing to nearly 98% of the total.

Revenue from the COVID and allied segments was down to just 110 million rupees, from 660 million rupees a year before.

Shares of Dr. Lal PathLabs fell as much as 3.2% to 1,888.10 rupees after reporting results.

($1 = 81.7800 Indian rupees)

(Reporting by Nandan Mandayam in Bengaluru; Editing by Sonia Cheema)

(([email protected]; Mobile: +91 9591011727;))